On Friday, Harrow received a positive adjustment to its Relative Strength (RS) Rating, from 80 to 84.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily tracks price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves.
Harrow is now considered extended and out of buy range after clearing a 20.31 buy point in a third-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Harrow showed 0% EPS growth in its most recent report, while sales growth came in at 38%. Look for the next report on or around Aug. 12.
The company earns the No. 113 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
